Disappointing study results for Ohr
March 27, 2015 at 13:16 PM EDT
Ohr
Pharmaceutical Inc. (Nasdaq: OHRP) reported disappointing results from a
Phase II study of its eye drop solution OHR-102 sending the stock price
plunging $5.69 to $3.04.
